48 related articles for article (PubMed ID: 2838572)
1. Distinct genetic architectures and environmental factors associate with host response to the γ2-herpesvirus infections.
Sallah N; Miley W; Labo N; Carstensen T; Fatumo S; Gurdasani D; Pollard MO; Dilthey AT; Mentzer AJ; Marshall V; Cornejo Castro EM; Pomilla C; Young EH; Asiki G; Hibberd ML; Sandhu M; Kellam P; Newton R; Whitby D; Barroso I
Nat Commun; 2020 Jul; 11(1):3849. PubMed ID: 32737300
[TBL] [Abstract][Full Text] [Related]
2. Antibodies to a strain-specific citrullinated Epstein-Barr virus peptide diagnoses rheumatoid arthritis.
Trier NH; Holm BE; Heiden J; Slot O; Locht H; Lindegaard H; Svendsen A; Nielsen CT; Jacobsen S; Theander E; Houen G
Sci Rep; 2018 Feb; 8(1):3684. PubMed ID: 29487382
[TBL] [Abstract][Full Text] [Related]
3. Rheumatoid arthritis patient antibodies highly recognize IL-2 in the immune response pathway involving IRF5 and EBV antigens.
Bo M; Niegowska M; Erre GL; Piras M; Longu MG; Manchia P; Manca M; Passiu G; Sechi LA
Sci Rep; 2018 Jan; 8(1):1789. PubMed ID: 29379122
[TBL] [Abstract][Full Text] [Related]
4. Uncovering the Role of Epstein-Barr Virus Infection Markers for Remission in Rheumatoid Arthritis.
Banko A; Cirkovic A; Jeremic I; Basaric M; Grk M; Miskovic R; Lazarevic I; Miljanovic D
Biomedicines; 2023 Aug; 11(9):. PubMed ID: 37760816
[TBL] [Abstract][Full Text] [Related]
5. EBV-positive human sera contain antibodies against the EBV BMRF-2 protein.
Xiao J; Palefsky JM; Herrera R; Sunshine C; Tugizov SM
Virology; 2009 Oct; 393(1):151-9. PubMed ID: 19698968
[TBL] [Abstract][Full Text] [Related]
6. Serum antibody response to lytic and latent Epstein-Barr virus antigens in undifferentiated nasopharyngeal carcinoma patients from an area of nonendemicity.
Tedeschi R; Pin E; Martorelli D; Bidoli E; Marus A; Pratesi C; Bortolin MT; Zanussi S; Vaccher E; Dolcetti R; De Paoli P
Clin Vaccine Immunol; 2007 Apr; 14(4):435-41. PubMed ID: 17329446
[TBL] [Abstract][Full Text] [Related]
7. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses.
Leen A; Meij P; Redchenko I; Middeldorp J; Bloemena E; Rickinson A; Blake N
J Virol; 2001 Sep; 75(18):8649-59. PubMed ID: 11507210
[TBL] [Abstract][Full Text] [Related]
8. The Epstein-Barr virus in autoimmunity.
Vaughan JH
Springer Semin Immunopathol; 1995; 17(2-3):203-30. PubMed ID: 8571169
[No Abstract] [Full Text] [Related]
9. Development of a recombinant enzyme-linked immunosorbent assay for detection of antibodies against Epstein-Barr virus nuclear antigens 2A and 2B.
Geertsen R; Espander-Jansson A; Dobec M; Price P; Wunderli W; Rymo L
J Clin Microbiol; 1994 Jan; 32(1):112-20. PubMed ID: 8126164
[TBL] [Abstract][Full Text] [Related]
10. Immune regulation in Epstein-Barr virus-associated diseases.
Khanna R; Burrows SR; Moss DJ
Microbiol Rev; 1995 Sep; 59(3):387-405. PubMed ID: 7565411
[TBL] [Abstract][Full Text] [Related]
11. Relationship between antibody production to Epstein-Barr virus (EBV) early antigens and various EBV-related diseases.
Ooka T; de Turenne-Tessier M; Stolzenberg MC
Springer Semin Immunopathol; 1991; 13(2):233-47. PubMed ID: 1664988
[No Abstract] [Full Text] [Related]
12. Molecular basis for Epstein-Barr virus induced pathogenesis and disease.
Sample C; Kieff E
Springer Semin Immunopathol; 1991; 13(2):133-46. PubMed ID: 1664982
[No Abstract] [Full Text] [Related]
13. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
Rowe M; Lear AL; Croom-Carter D; Davies AH; Rickinson AB
J Virol; 1992 Jan; 66(1):122-31. PubMed ID: 1309242
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus.
Rowe M; Finke J; Szigeti R; Klein G
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1217-28. PubMed ID: 2838572
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
Young LS; Dawson CW; Clark D; Rupani H; Busson P; Tursz T; Johnson A; Rickinson AB
J Gen Virol; 1988 May; 69 ( Pt 5)():1051-65. PubMed ID: 2836550
[TBL] [Abstract][Full Text] [Related]
16. Immune response to different sequences of the EBNA I molecule in Epstein-Barr virus-related disorders and in autoimmune diseases.
Marchini B; Dolcher MP; Sabbatini A; Klein G; Migliorini P
J Autoimmun; 1994 Apr; 7(2):179-91. PubMed ID: 7518683
[TBL] [Abstract][Full Text] [Related]
17. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in different groups of individuals.
Seigneurin JM; Lavoue MF; Genoulaz O; Bornkamm GW; Lenoir GM
Int J Cancer; 1987 Sep; 40(3):349-53. PubMed ID: 3040599
[TBL] [Abstract][Full Text] [Related]
18. T cell recognition of Epstein-Barr virus associated lymphomas.
Rickinson AB; Murray RJ; Brooks J; Griffin H; Moss DJ; Masucci MG
Cancer Surv; 1992; 13():53-80. PubMed ID: 1330300
[TBL] [Abstract][Full Text] [Related]
19. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1.
Kis LL; Takahara M; Nagy N; Klein G; Klein E
Immunol Lett; 2006 Apr; 104(1-2):83-8. PubMed ID: 16386314
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
